Journal article

The bosentan patient registry: long-term survival in pulmonary arterial hypertension

A Keogh, G Strange, K McNeil, TJ Williams, E Gabbay, S Proudman, RG Weintraub, J Wlodarczyk, B Dalton

Internal Medicine Journal | WILEY-BLACKWELL | Published : 2011

Grants

Funding Acknowledgements

AK has participated in clinical trials and received research funding from Actelion Pharmaceuticals Australia, Bayer, GSK, Heartware, Myogen, Novartis, Pfizer, Roche, Scios, Ventracor and Wyeth. She has served on Advisory Boards for Actelion Pharmaceuticals Australia, Bayer, CSL, GSK, Novartis, Pfizer, Roche and Ventracor. KM has received travel support from Actelion Pharmaceuticals Australia as well as honoraria for speaking and consulting engagements. He is a member of the Advisory Boards for Actelion Pharmaceuticals Australia and GSK, and has received consultancy honoraria from Bayer-Schering. TJW is a PAH Scientific Advisory Board member for Actelion Pharmaceuticals Australia, CSL and GSK. He has received travel and research support/investigator payments from Actelion and research support/investigator payments from Bayer, CSL, Pfizer and United Therapeutics. EG has received research support from Actelion Pharmaceuticals Australia, CSL as well as honoraria for speaking and consulting engagements, and as a member of the Actelion, CSL and GSK Advisory Boards. The Heart and Lung Transplant Foundation of WA, of which EG is chair has received educational grants from Actelion and CSL. EG has also received travel support from Bayer-Schering the manufacturers of Iloprost, Encysive Pharmaceuticals, the manufacturers of Sitaxentan and GSK, the distributors of Ambrisentan in Australia. RGW has received travel and research support from Actelion Pharmaceuticals Australia as well as honoraria for speaking and consulting engagements, and has served on Advisory Boards for Actelion Pharmaceuticals Australia, CSL and GSK. SP has received travel support from Actelion Pharmaceuticals Australia as well as honoraria for speaking and consulting engagements, and has served on Advisory Boards for Actelion Pharmaceuticals Australia, CSL and GSK. BD and JW have received consulting fees from Actelion. GS has no conflicts to declare.